Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Determining the Cytosolic Stability of Small DNA Nanostructures In Cellula.
Mathur D, Rogers KE, Díaz SA, Muroski ME, Klein WP, Nag OK, Lee K, Field LD, Delehanty JB, Medintz IL. Mathur D, et al. Among authors: rogers ke. Nano Lett. 2022 Jun 22;22(12):5037-5045. doi: 10.1021/acs.nanolett.2c00917. Epub 2022 May 17. Nano Lett. 2022. PMID: 35580267 Free PMC article.
Synergistic effects of inhaled aztreonam plus tobramycin on hypermutable cystic fibrosis Pseudomonas aeruginosa isolates in a dynamic biofilm model evaluated by mechanism-based modelling and whole genome sequencing.
Breen SKJ, Harper M, López-Causapé C, Rogers KE, Tait JR, Smallman TR, Lang Y, Lee WL, Zhou J, Zhang Y, Bulitta JB, Nation RL, Oliver A, Boyce JD, Landersdorfer CB. Breen SKJ, et al. Among authors: rogers ke. Int J Antimicrob Agents. 2024 Mar 30;63(6):107161. doi: 10.1016/j.ijantimicag.2024.107161. Online ahead of print. Int J Antimicrob Agents. 2024. PMID: 38561094 Free article.
Ceftolozane-Tazobactam against Pseudomonas aeruginosa Cystic Fibrosis Clinical Isolates in the Hollow-Fiber Infection Model: Challenges Imposed by Hypermutability and Heteroresistance.
Tait JR, Harper M, Cortés-Lara S, Rogers KE, López-Causapé C, Smallman TR, Lang Y, Lee WL, Zhou J, Bulitta JB, Nation RL, Boyce JD, Oliver A, Landersdorfer CB. Tait JR, et al. Among authors: rogers ke. Antimicrob Agents Chemother. 2023 Aug 17;67(8):e0041423. doi: 10.1128/aac.00414-23. Epub 2023 Jul 10. Antimicrob Agents Chemother. 2023. PMID: 37428034 Free PMC article.
Ceftolozane/tazobactam plus tobramycin against free-floating and biofilm bacteria of hypermutable Pseudomonas aeruginosa epidemic strains: Resistance mechanisms and synergistic activity.
Agyeman AA, López-Causapé C, Rogers KE, Lucas DD, Cortés-Lara S, Gomis-Font MA, Fraile-Ribot P, Figuerola J, Lang Y, Franklyn ERT, Lee WL, Zhou J, Zhang Y, Bulitta JB, Boyce JD, Nation RL, Oliver A, Landersdorfer CB. Agyeman AA, et al. Among authors: rogers ke. Int J Antimicrob Agents. 2023 Sep;62(3):106887. doi: 10.1016/j.ijantimicag.2023.106887. Epub 2023 Jun 12. Int J Antimicrob Agents. 2023. PMID: 37315906
Penicillin G concentrations required for prophylaxis against Group A Streptococcus infection evaluated using a hollow fibre model and mathematical modelling.
Tait JR, Barnett TC, Rogers KE, Lee WL, Page-Sharp M, Manning L, Boyd BJ, Carapetis JR, Nation RL, Landersdorfer CB. Tait JR, et al. Among authors: rogers ke. J Antimicrob Chemother. 2022 Jun 29;77(7):1923-1930. doi: 10.1093/jac/dkac124. J Antimicrob Chemother. 2022. PMID: 35470370 Free PMC article.
Effect of Different Piperacillin-Tazobactam Dosage Regimens on Synergy of the Combination with Tobramycin against Pseudomonas aeruginosa for the Pharmacokinetics of Critically Ill Patients in a Dynamic Infection Model.
Tait JR, Bilal H, Rogers KE, Lang Y, Kim TH, Zhou J, Wallis SC, Bulitta JB, Kirkpatrick CMJ, Paterson DL, Lipman J, Bergen PJ, Roberts JA, Nation RL, Landersdorfer CB. Tait JR, et al. Among authors: rogers ke. Antibiotics (Basel). 2022 Jan 13;11(1):101. doi: 10.3390/antibiotics11010101. Antibiotics (Basel). 2022. PMID: 35052977 Free PMC article.
54 results